Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2

Hitomi Nagayama, Katsuaki Sato, Mariko Morishita, Kaoru Uchimaru, Naoki Oyaizu, Takeshi Inazawa, Tomoko Yamasaki, Makoto Enomoto, Takashi Nakaoka, Tetsuya Nakamura, Taira Maekawa, Akifumi Yamamoto, Shinji Shimada, Toshiaki Saida, Yutaka Kawakami, Shigetaka Asano, Kenzaburo Tani, Tsuneo A. Takahashi, Naohide Yamashita

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

We conducted a pilot study to assess the feasibility and efficacy of immunotherapy for stage IV malignant melanoma patients resistant to conventional therapies involving vaccination with mature dendritic cells (mDCs) combined with administration of low dose interleukin-2, Autologous monocytes were harvested from a single apheresis and cultured for 7 days with granulocyte-macrophage colony-stimulating factor and interleukin-4, yielding immature dendritic cells (iDCs), which were then cryopreserved until use. For 4 days prior to vaccination, iDCs were exposed to autologous tumour lysate combined with tumour necrosis factor-α to induce terminal differentiation into mDCs. Patients were then vaccinated weekly with 107 mDCs for 10 weeks and given 350-700 kIU of interleukin-2 three times per week. Of the 10 patients in the study, one showed stable disease, seven showed progressive disease, and two showed mixed responses, including partial tumour regression, and were therefore given 20 additional injections. Only minimal adverse events were noted, including localized skin reactions and mild fever (NIH-CTC grade 0-1). Median survival from the first vaccination was 240 days (range 31-735 days). In vitro, melanoma patient-derived dendritic cells (DCs) showed reduced cell surface expression of CD1a antigen on iDCs and reduced CD86 and HLA-DR expression on mDCs. In addition, antigen uptake, chemotaxis and antigen presentation were all attenuated in DCs from the patients. In summary, although improvement of clinical efficacy will require further research, autologous tumour lysate-pulsed monocytederived mDCs could be safely harvested, cryopreserved and administrated to patients without obvious complications.

Original languageEnglish
Pages (from-to)521-530
Number of pages10
JournalMelanoma Research
Volume13
Issue number5
DOIs
Publication statusPublished - 2003 Oct

Fingerprint

Dendritic Cells
Interleukin-2
Monocytes
Melanoma
Vaccination
Neoplasms
Clinical Studies
Blood Component Removal
Antigen Presentation
HLA-DR Antigens
Chemotaxis
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-4
Immunotherapy
Fever
Tumor Necrosis Factor-alpha
Antigens
Skin
Injections
Survival

Keywords

  • Dendritic cells
  • Human
  • Immunotherapy
  • Melanoma
  • Vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Dermatology

Cite this

Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. / Nagayama, Hitomi; Sato, Katsuaki; Morishita, Mariko; Uchimaru, Kaoru; Oyaizu, Naoki; Inazawa, Takeshi; Yamasaki, Tomoko; Enomoto, Makoto; Nakaoka, Takashi; Nakamura, Tetsuya; Maekawa, Taira; Yamamoto, Akifumi; Shimada, Shinji; Saida, Toshiaki; Kawakami, Yutaka; Asano, Shigetaka; Tani, Kenzaburo; Takahashi, Tsuneo A.; Yamashita, Naohide.

In: Melanoma Research, Vol. 13, No. 5, 10.2003, p. 521-530.

Research output: Contribution to journalArticle

Nagayama, H, Sato, K, Morishita, M, Uchimaru, K, Oyaizu, N, Inazawa, T, Yamasaki, T, Enomoto, M, Nakaoka, T, Nakamura, T, Maekawa, T, Yamamoto, A, Shimada, S, Saida, T, Kawakami, Y, Asano, S, Tani, K, Takahashi, TA & Yamashita, N 2003, 'Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2', Melanoma Research, vol. 13, no. 5, pp. 521-530. https://doi.org/10.1097/00008390-200310000-00011
Nagayama, Hitomi ; Sato, Katsuaki ; Morishita, Mariko ; Uchimaru, Kaoru ; Oyaizu, Naoki ; Inazawa, Takeshi ; Yamasaki, Tomoko ; Enomoto, Makoto ; Nakaoka, Takashi ; Nakamura, Tetsuya ; Maekawa, Taira ; Yamamoto, Akifumi ; Shimada, Shinji ; Saida, Toshiaki ; Kawakami, Yutaka ; Asano, Shigetaka ; Tani, Kenzaburo ; Takahashi, Tsuneo A. ; Yamashita, Naohide. / Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. In: Melanoma Research. 2003 ; Vol. 13, No. 5. pp. 521-530.
@article{0773435bd244476e9e80728155e49d5b,
title = "Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2",
abstract = "We conducted a pilot study to assess the feasibility and efficacy of immunotherapy for stage IV malignant melanoma patients resistant to conventional therapies involving vaccination with mature dendritic cells (mDCs) combined with administration of low dose interleukin-2, Autologous monocytes were harvested from a single apheresis and cultured for 7 days with granulocyte-macrophage colony-stimulating factor and interleukin-4, yielding immature dendritic cells (iDCs), which were then cryopreserved until use. For 4 days prior to vaccination, iDCs were exposed to autologous tumour lysate combined with tumour necrosis factor-α to induce terminal differentiation into mDCs. Patients were then vaccinated weekly with 107 mDCs for 10 weeks and given 350-700 kIU of interleukin-2 three times per week. Of the 10 patients in the study, one showed stable disease, seven showed progressive disease, and two showed mixed responses, including partial tumour regression, and were therefore given 20 additional injections. Only minimal adverse events were noted, including localized skin reactions and mild fever (NIH-CTC grade 0-1). Median survival from the first vaccination was 240 days (range 31-735 days). In vitro, melanoma patient-derived dendritic cells (DCs) showed reduced cell surface expression of CD1a antigen on iDCs and reduced CD86 and HLA-DR expression on mDCs. In addition, antigen uptake, chemotaxis and antigen presentation were all attenuated in DCs from the patients. In summary, although improvement of clinical efficacy will require further research, autologous tumour lysate-pulsed monocytederived mDCs could be safely harvested, cryopreserved and administrated to patients without obvious complications.",
keywords = "Dendritic cells, Human, Immunotherapy, Melanoma, Vaccine",
author = "Hitomi Nagayama and Katsuaki Sato and Mariko Morishita and Kaoru Uchimaru and Naoki Oyaizu and Takeshi Inazawa and Tomoko Yamasaki and Makoto Enomoto and Takashi Nakaoka and Tetsuya Nakamura and Taira Maekawa and Akifumi Yamamoto and Shinji Shimada and Toshiaki Saida and Yutaka Kawakami and Shigetaka Asano and Kenzaburo Tani and Takahashi, {Tsuneo A.} and Naohide Yamashita",
year = "2003",
month = "10",
doi = "10.1097/00008390-200310000-00011",
language = "English",
volume = "13",
pages = "521--530",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2

AU - Nagayama, Hitomi

AU - Sato, Katsuaki

AU - Morishita, Mariko

AU - Uchimaru, Kaoru

AU - Oyaizu, Naoki

AU - Inazawa, Takeshi

AU - Yamasaki, Tomoko

AU - Enomoto, Makoto

AU - Nakaoka, Takashi

AU - Nakamura, Tetsuya

AU - Maekawa, Taira

AU - Yamamoto, Akifumi

AU - Shimada, Shinji

AU - Saida, Toshiaki

AU - Kawakami, Yutaka

AU - Asano, Shigetaka

AU - Tani, Kenzaburo

AU - Takahashi, Tsuneo A.

AU - Yamashita, Naohide

PY - 2003/10

Y1 - 2003/10

N2 - We conducted a pilot study to assess the feasibility and efficacy of immunotherapy for stage IV malignant melanoma patients resistant to conventional therapies involving vaccination with mature dendritic cells (mDCs) combined with administration of low dose interleukin-2, Autologous monocytes were harvested from a single apheresis and cultured for 7 days with granulocyte-macrophage colony-stimulating factor and interleukin-4, yielding immature dendritic cells (iDCs), which were then cryopreserved until use. For 4 days prior to vaccination, iDCs were exposed to autologous tumour lysate combined with tumour necrosis factor-α to induce terminal differentiation into mDCs. Patients were then vaccinated weekly with 107 mDCs for 10 weeks and given 350-700 kIU of interleukin-2 three times per week. Of the 10 patients in the study, one showed stable disease, seven showed progressive disease, and two showed mixed responses, including partial tumour regression, and were therefore given 20 additional injections. Only minimal adverse events were noted, including localized skin reactions and mild fever (NIH-CTC grade 0-1). Median survival from the first vaccination was 240 days (range 31-735 days). In vitro, melanoma patient-derived dendritic cells (DCs) showed reduced cell surface expression of CD1a antigen on iDCs and reduced CD86 and HLA-DR expression on mDCs. In addition, antigen uptake, chemotaxis and antigen presentation were all attenuated in DCs from the patients. In summary, although improvement of clinical efficacy will require further research, autologous tumour lysate-pulsed monocytederived mDCs could be safely harvested, cryopreserved and administrated to patients without obvious complications.

AB - We conducted a pilot study to assess the feasibility and efficacy of immunotherapy for stage IV malignant melanoma patients resistant to conventional therapies involving vaccination with mature dendritic cells (mDCs) combined with administration of low dose interleukin-2, Autologous monocytes were harvested from a single apheresis and cultured for 7 days with granulocyte-macrophage colony-stimulating factor and interleukin-4, yielding immature dendritic cells (iDCs), which were then cryopreserved until use. For 4 days prior to vaccination, iDCs were exposed to autologous tumour lysate combined with tumour necrosis factor-α to induce terminal differentiation into mDCs. Patients were then vaccinated weekly with 107 mDCs for 10 weeks and given 350-700 kIU of interleukin-2 three times per week. Of the 10 patients in the study, one showed stable disease, seven showed progressive disease, and two showed mixed responses, including partial tumour regression, and were therefore given 20 additional injections. Only minimal adverse events were noted, including localized skin reactions and mild fever (NIH-CTC grade 0-1). Median survival from the first vaccination was 240 days (range 31-735 days). In vitro, melanoma patient-derived dendritic cells (DCs) showed reduced cell surface expression of CD1a antigen on iDCs and reduced CD86 and HLA-DR expression on mDCs. In addition, antigen uptake, chemotaxis and antigen presentation were all attenuated in DCs from the patients. In summary, although improvement of clinical efficacy will require further research, autologous tumour lysate-pulsed monocytederived mDCs could be safely harvested, cryopreserved and administrated to patients without obvious complications.

KW - Dendritic cells

KW - Human

KW - Immunotherapy

KW - Melanoma

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=12444309359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444309359&partnerID=8YFLogxK

U2 - 10.1097/00008390-200310000-00011

DO - 10.1097/00008390-200310000-00011

M3 - Article

C2 - 14512794

AN - SCOPUS:12444309359

VL - 13

SP - 521

EP - 530

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 5

ER -